CommercialCoverageMedium impact
08.00.13an, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Hematology, Oncology +3 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a policy update for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) treatments under commercial insurance plans. The policy was recently posted and will become effective April 1, 2026, likely containing updated coverage criteria, prior authorization requirements, or billing guidelines for immunoglobulin therapies.
Action Required
Before April 1, 2026: Billing team must review the full policy text at the provided URL to identify specific changes to IVIG/SCIG coverage, prior authorization requirements, or billing procedures. Update billing software and staff training materials based on the new policy requirements. Contact commercial payers to clarify any coverage changes that may affect claim processing.